Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
protein degradation
Biotech
Roche bets $700M upfront on Nurix’s late-phase BTK degrader
Roche is securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 blood cancer trial.
Nick Paul Taylor
Jun 8, 2026 4:41am
French biotech pens $128M deal for Kezar protein degrader work
Mar 12, 2026 9:00am
Cullgen ditches reverse merger with Pulmatrix to go with Gyre
Mar 2, 2026 10:55am
J&J, Google venture arms line up to back EpiBiologics' series B
Jan 8, 2026 9:05am
Amgen weaves in UK biotech with up to $840M acquisition
Jan 6, 2026 10:35am
Amphista's targeted glue sticks the landing in early AML test
Dec 8, 2025 7:40am
